Blood test measuring p-tau217 may forecast Alzheimer-related cognitive decline in seniors
सिर्फ तथ्य

Blood test measuring p-tau217 may forecast Alzheimer-related cognitive decline in seniors

सारांश

A Mayo Clinic study published in JAMA Neurology found that blood levels of phosphorylated tau 217 can estimate a 5- to 10-year risk of mild cognitive impairment in adults aged 60 to 90.

A Mayo Clinic investigation involving 2,178 cognitively normal adults aged 60 to 90 linked higher blood concentrations of phosphorylated tau 217 (p-tau217) to an increased risk of developing mild cognitive impairment within five to ten years. The analysis, published in JAMA Neurology, also accounted for age, gender and the presence of the APOE ε4 allele, a known genetic risk factor for Alzheimer’s disease.

Risk estimates varied markedly by age. At the same elevated p-tau217 level, a 65-year-old had an estimated five-year risk of 6 %, whereas an 85-year-old faced a 37 % risk, the researchers reported.

"The test tells you, just by taking a blood sample, whether someone has that pathology in the brain," senior author Clifford Jack Jr., a Mayo Clinic neuroradiologist, said in an interview with Fox News Digital.

The authors noted that blood-based detection of p-tau217 could be less invasive and more scalable than PET imaging for amyloid plaques, another hallmark of Alzheimer’s disease. First author Alicia Algeciras-Schimnich, Ph.D., said the aim is to provide a personalized risk estimate rather than a simple positive/negative result.

Researchers cautioned that the model was derived from a cohort in southeast Minnesota and may not represent the broader U.S. population. They emphasized that the test is not yet suitable for routine screening of asymptomatic individuals because no approved treatments exist for pre-symptomatic disease.

"There is no treatment that’s been approved for people who are asymptomatic but have the disease in the brain. Therefore, there’s no reason to do the test," Jack added.

The team suggested that if preventive therapies become available, the blood test could help clinicians and patients discuss potential benefits and risks more effectively. Further validation in diverse populations is required before broader clinical use.

स्रोत

Fox News

पहली बार यहां रिपोर्ट किया गया

पढ़ते रहें — निःशुल्क

समाचार फ़ॉलो करने के लिए मुफ़्त खाता बनाएँ। कार्ड की आवश्यकता नहीं।